Skip to content
PharmAlert — Clinical Decision Support

PRIORITISATION

Why this alert, and why first.

A check nobody can inspect is a check nobody will trust. Every ranking PharmAlert produces can be opened up and read.

How the score is built

Three things determine where a finding appears: how serious the risk is, how much this particular patient's circumstances change that risk, and how well established the underlying evidence is. Nothing else — no engagement optimisation, no hidden weighting.

Inspect a ranking

Score inspector

CriticalPA-INT-002

Clarithromycin + Simvastatin

Clarithromycin inhibits CYP3A4, raising simvastatin exposure several-fold. Risk of myopathy and rhabdomyolysis.

Well documented · Established

SuggestedSuspend the statin for the antibiotic course, or use azithromycin — confirm against local formulary.

Severity · critical
100
Patient context · age 82 (+20) · eGFR 38 (+20)
+40
Evidence grade · established
+10
Override history · none
0
Rank 1 of 1
150

Demonstration only, using fictional patients. Not for clinical use.

Evidence grading

ESTABLISHED
Well-documented, clinically significant, widely recognised.
PROBABLE
Supported by evidence, with some variation in the literature.
THEORETICAL
Mechanistically plausible, limited clinical reporting.

Human in the loop

Every alert can be overridden with a recorded reason. Overridden alerts don't disappear — they move out of the way and stay in the audit record, where clinical governance teams can review patterns over time.

PharmAlert supports the decision. It does not make it.

Test the reasoning against your own patients.

Discuss a clinical pilot